These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25789050)

  • 21. Treatment of recurrent and platinum-refractory stage IV non-small cell lung cancer with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent.
    Saxena A; Schneider BJ; Christos PJ; Audibert LF; Cagney JM; Scheff RJ
    Med Oncol; 2016 Feb; 33(2):13. PubMed ID: 26749586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).
    Morgensztern D; Cobo M; Ponce Aix S; Postmus PE; Lewanski CR; Bennouna J; Fischer JR; Juan-Vidal O; Stewart DJ; Fasola G; Ardizzoni A; Bhore R; Wolfsteiner M; Talbot DC; Jin Ong T; Govindan R; On Behalf Of The Abound L Investigators
    Cancer; 2018 Dec; 124(24):4667-4675. PubMed ID: 30383906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma.
    Huang Y; Liang W; Yang Y; Zhao L; Zhao H; Wu X; Zhao Y; Zhang Y; Zhang L
    BMC Cancer; 2016 Jul; 16():464. PubMed ID: 27411683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer.
    Huang L; Chen S; Yao L; Liu G; Wu J; Shao Z
    Int J Nanomedicine; 2015; 10():1969-75. PubMed ID: 25792830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma.
    Wang HY; Yao ZH; Tang H; Zhao Y; Zhang XS; Yao SN; Yang SJ; Liu YY
    Onco Targets Ther; 2016; 9():5663-5669. PubMed ID: 27713635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Albumin-bound paclitaxel for the treatment of refractory or relapsed small-cell lung cancer.
    Yoshida H; Kim YH; Ozasa H; Nagai H; Sakamori Y; Nakaoku T; Yagi Y; Tsuji T; Nomizo T; Mishima M
    Mol Clin Oncol; 2016 Jul; 5(1):213-215. PubMed ID: 27330801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of salvage nano-particle albumin bound paclitaxel in recurrent cervical cancer: a feasibility study.
    Minion LE; Chase DM; Farley JH; Willmott LJ; Monk BJ
    Gynecol Oncol Res Pract; 2016; 3():4. PubMed ID: 27231575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of nanoparticle albumin-bound paclitaxel, carboplatin and trastuzumab in women with human epidermal growth factor receptor 2-overexpressing breast cancer.
    Tezuka K; Takashima T; Kashiwagi S; Kawajiri H; Tokunaga S; Tei S; Nishimura S; Yamagata S; Noda S; Nishimori T; Mizuyama Y; Sunami T; Ikeda K; Ogawa Y; Onoda N; Ishikawa T; Kudoh S; Takada M; Hirakawa K
    Mol Clin Oncol; 2017 Apr; 6(4):534-538. PubMed ID: 28413662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer.
    Ciruelos E; Apellániz-Ruiz M; Cantos B; Martinez-Jáñez N; Bueno-Muiño C; Echarri MJ; Enrech S; Guerra JA; Manso L; Pascual T; Dominguez C; Gonzalo JF; Sanz JL; Rodriguez-Antona C; Sepúlveda JM
    Oncologist; 2019 Nov; 24(11):e1024-e1033. PubMed ID: 31023863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I Study of Triweekly Nab-Paclitaxel Combined with S-1 in Patients with HER2-negative Metastatic Breast Cancer.
    Sakaguchi K; Nakatsukasa K; Taguchi T
    Anticancer Res; 2016 Dec; 36(12):6515-6519. PubMed ID: 27919976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Elderly Patients with Metastatic Breast Cancer: A Meta-Analysis.
    Li X; Kwon H
    J Clin Med; 2019 Oct; 8(10):. PubMed ID: 31618921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy of supportive care for albumin-bound paclitaxel(nab-paclitaxel)in 20 patients with metastatic breast cancer].
    Yamada C; Yonezawa M; Shimizu Y; Taga R; Kashihara H; Tsuji K; Murata T; Yoshino H
    Gan To Kagaku Ryoho; 2014 Jan; 41(1):77-81. PubMed ID: 24423956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potentially Overestimated Efficacy of Nanoparticle Albumin-bound Paclitaxel compared with Solvent-based Paclitaxel in Breast Cancer: A Systemic Review and Meta-analysis.
    Li BX; Chen XJ; Ding TJ; Liu YH; Ma TT; Zhang GL; Wang XM
    J Cancer; 2021; 12(17):5164-5172. PubMed ID: 34335933
    [No Abstract]   [Full Text] [Related]  

  • 34. De-escalated neoadjuvant therapy with nanoparticle albumin-bound paclitaxel and trastuzumab for low-risk pure HER2 breast cancer.
    Tanaka S; Matsunami N; Morishima H; Oda N; Takashima T; Noda S; Kashiwagi S; Tauchi Y; Asano Y; Kimura K; Fujioka H; Terasawa R; Kawaguchi K; Ikari A; Morimoto T; Michishita S; Kobayashi T; Sakane J; Nitta T; Sato N; Hokimoto N; Nishida Y; Iwamoto M
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1099-1104. PubMed ID: 30963212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Final Effectiveness and Safety Results of NABUCCO: Real-World Data From a Noninterventional, Prospective, Multicenter Study in 697 Patients With Metastatic Breast Cancer Treated With nab-Paclitaxel.
    Marschner N; Salat C; Söling U; Hansen R; Grebhardt S; Harde J; Nusch A; Potthoff K
    Clin Breast Cancer; 2018 Dec; 18(6):e1323-e1337. PubMed ID: 30100104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE).
    Woodward N; De Boer RH; Redfern A; White M; Young J; Truman M; Beith J
    Clin Breast Cancer; 2019 Jun; 19(3):216-224. PubMed ID: 30922805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib.
    Kaklamani VG; Siziopikou K; Scholtens D; Lacouture M; Gordon J; Uthe R; Meservey C; Hansen N; Khan SA; Jeruss JS; Bethke K; Cianfrocca M; Rosen S; Von Roenn J; Wayne J; Parimi V; Jovanovic B; Gradishar W
    Breast Cancer Res Treat; 2012 Apr; 132(3):833-42. PubMed ID: 21359953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I Study of Combination Therapy With Weekly Nanoparticle Albumin-bound Paclitaxel and Cyclophosphamide in Metastatic Breast Cancer Patients.
    Ota D; Akatsuka S; Nishi T; Kato T; Takeuchi M; Tsuji M; Fukuuchi A
    Anticancer Res; 2019 Dec; 39(12):6903-6907. PubMed ID: 31810960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial.
    Futamura M; Nagao Y; Ishihara K; Takeuchi M; Nakada T; Kawaguchi Y; Asano M; Kumazawa I; Shiroko T; Morimitsu K; Mori R; Nawa M; Shimokawa T; Yoshida K
    Breast Cancer; 2017 Jul; 24(4):615-623. PubMed ID: 28050738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial.
    Tokunaga S; Takashima T; Kashiwagi S; Noda S; Kawajiri H; Tokumoto M; Nishimura S; Nishimori T; Ikeda K; Ogawa Y; Mizuyama Y; Sunami T; Tezuka K; Yamagata S; Ishikawa T; Kudoh S; Takada M; Hirakawa K; Ohira M
    Anticancer Res; 2019 Apr; 39(4):2053-2059. PubMed ID: 30952749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.